Latest Insider Transactions at Janux Therapeutics, Inc. (JANX)
This section provides a real-time view of insider transactions for Janux Therapeutics, Inc. (JANX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Janux Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Janux Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 15
2021
|
Tighe Reardon Acting Chief Financial Officer |
BUY
Open market or private purchase
|
Indirect |
629,411
+12.32%
|
$10,699,987
$17.0 P/Share
|
|
Jun 15
2021
|
Tighe Reardon Acting Chief Financial Officer |
BUY
Conversion of derivative security
|
Indirect |
3,850,081
+36.52%
|
-
|
|
Jun 15
2021
|
Peter A. Thompson Director |
BUY
Open market or private purchase
|
Indirect |
705,853
+23.49%
|
$11,999,501
$17.0 P/Share
|
|
Jun 15
2021
|
Peter A. Thompson Director |
BUY
Conversion of derivative security
|
Indirect |
2,336,911
+42.5%
|
-
|
|
Jun 15
2021
|
Bregua Corp > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
58,823
+1.54%
|
$999,991
$17.0 P/Share
|
|
Jun 15
2021
|
Bregua Corp > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
3,690,427
+27.43%
|
-
|
|
Jun 15
2021
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
705,853
+23.49%
|
$11,999,501
$17.0 P/Share
|
|
Jun 15
2021
|
Orbimed Advisors LLC Director |
BUY
Conversion of derivative security
|
Indirect |
2,336,911
+42.5%
|
-
|
|
Jun 15
2021
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
2,941,176
+20.9%
|
$49,999,992
$17.0 P/Share
|
|
Jun 15
2021
|
Ra Capital Management, L.P. |
BUY
Conversion of derivative security
|
Indirect |
5,729,468
+44.64%
|
-
|